Horizant gabapentin enacarbil regulatory update

FDA accepted for review a response from GlaxoSmithKline to a February complete response letter for Horizant gabapentin enacarbil (XP13512,

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE